Business
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information.Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera
About this update from Biofrontera Inc.
[{"type":"image","alt":"Biofrontera Inc.","displaySize":"","headline":null,"caption":"Biofrontera Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bVH36b1WxYUx1e199mXo7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information.","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection.","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":443,"olType":false},{"type":"text","content":"WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol-free formulation of Ameluz® nanoemulsion gel in the US Food and Drug Administration’s (FDA’s) publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book).","length":467,"tagName":"p"},{"type":"text","content":"The Orange Book is a key reference for healthcare providers, pharmacists, and payers and is the definitive source for identifying FDA-approved drug products. Inclusion of a drug in the Orange Book confirms that the FDA recognizes that the drug meets their rigorous standards for safety, efficacy, and quality. In addition, patents listed confer intellectual property protections which may include the drug’s composition, formulation, or specific uses. Listing of the patent for the propylene glycol-free formulation of Ameluz® prevents generic competition as long as the patent is valid, which...